Author

M. Martinez-Iniesta

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:DNA methylation· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Villanueva· 3 shared A. Bigas· 2 shared L. Espinosa· 2 shared L. Sole· 2 shared M. garrido· 2 shared M. Iglesias· 2 shared R. salazar· 2 shared Y. Guillen· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Villanueva

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 13, 2023

IKK1 kinase coordinates BRD4 and JAK/STAT signaling to subvert DNA damage-based anticancer therapy

L. Espinosa, I. Pecharroman Ruiz, L. Sole…·R. salazar

This study identifies IKK1's role in coordinating BRD4 and JAK/STAT signaling to resist DNA damage-based therapy in colorectal cancer.

DOI 10.1101/2023.06.13.544711

humanDNA methylation

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 8, 2021

Chemotherapy induces a YAP1-dependent fetal conversion to human Colorectal Cancer cells that is predictive of poor patient outcome

L. Sole, T. Lobo-Jarne, A. Villanueva…·L. Espinosa

The paper shows that sublethal chemotherapy induces a YAP1-dependent fetal phenotype in colorectal cancer cells, which predicts poor patient outcomes.

DOI 10.1101/2021.04.08.438915

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 8, 2021

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

E. Aliagas, A. Alay, M. Martinez-Iniesta…·E. Nadal

This study evaluates CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma, finding they reduce tumor growth and improve survival by inducing cell cycle arrest and senescence.

DOI 10.1101/2021.02.08.430196

mousebulk RNA-seq

𝕏 PostBluesky